We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Celsion Completes Ovarian Cancer Trial Enrollment, Stock Up
Read MoreHide Full Article
Celsion Corp.’s shares have rallied almost 20% on Wednesday after the company has announced a successful completion of enrollment in a phase Ib dose escalating study, evaluating its DNA-based immunotherapy, GEN-1 in combination with neoadjuvant chemotherapy for treatment of advanced ovarian cancer. This would allow a safety examination by the Company’s Data Safety Monitoring Board (DSMB) in mid-July this year.
The OVATION study was designed to identify a safe, tolerable and therapeutically active dose of GEN-1for future studies. The trial also assessed how cytokine-based compounds namely, GEN-1 directly affects ovarian cancer cells and the tumor microenvironment in newly diagnosed patients with Stage III and IV ovarian cancer, followed by an interval debulking surgery.
Of the 14 patients treated to date, two have demonstrated a complete response (CR), 10, a partial response (PR) and another two, a stable response. This showed a 100% disease control rate (DCR) and an 86% objective response rate (ORR). Of five patients treated in the highest dose cohort, there was a 100% objective response rate with one patient achieving complete response and four, showing partial responses.
The above research data was presented at the annual meeting of American Society of Clinical Oncology (ASCO) 2017.
However, Celsion’s shares have significantly underperformed the Zacks classified Medical-Biomed/Genetics industry so far this year. The stock has plunged 43.1% compared with the broader industry’s increase of 8.1%.
With enrolment completion, the company remains on track for an investigational new drug (IND) submission for phase I/II clinical study, combining GEN-1 with Roche Holding AG’s (RHHBY - Free Report) Avastin and Doxil in the recurrent population of ovarian cancer patients.
Apart from GEN-1 immunotherapy, another cancer program in Celsion’s portfolio is ThermoDox. It is currently under scrutiny in a phase III study for primary liver cancer and a phase II study for recurrent chest wall breast cancer.
Celsion currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in healthcare space are Bayer AG (BAYRY - Free Report) and Aduro BioTech, Inc. . While Bayer sports a Zacks Rank #1 (Strong Buy), Aduro carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Bayer’s earnings per share estimates have inched up from $8.85 to $8.93 for 2017 and from $9.53 to $9.61 for 2018, over the last 30 days. The company has delivered positive earnings surprises in three of the four trailing quarters with an average beat of 10.25%. Shares of Bayer have soared 22.6% so far this year.
Aduro’s loss per share estimates has shrunk from $1.60 to $1.46 for 2017 in the last 60 days. The company has delivered positive earnings surprises in two of the four trailing quarters with an average beat of 36.28%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Celsion Completes Ovarian Cancer Trial Enrollment, Stock Up
Celsion Corp.’s shares have rallied almost 20% on Wednesday after the company has announced a successful completion of enrollment in a phase Ib dose escalating study, evaluating its DNA-based immunotherapy, GEN-1 in combination with neoadjuvant chemotherapy for treatment of advanced ovarian cancer. This would allow a safety examination by the Company’s Data Safety Monitoring Board (DSMB) in mid-July this year.
The OVATION study was designed to identify a safe, tolerable and therapeutically active dose of GEN-1for future studies. The trial also assessed how cytokine-based compounds namely, GEN-1 directly affects ovarian cancer cells and the tumor microenvironment in newly diagnosed patients with Stage III and IV ovarian cancer, followed by an interval debulking surgery.
Of the 14 patients treated to date, two have demonstrated a complete response (CR), 10, a partial response (PR) and another two, a stable response. This showed a 100% disease control rate (DCR) and an 86% objective response rate (ORR). Of five patients treated in the highest dose cohort, there was a 100% objective response rate with one patient achieving complete response and four, showing partial responses.
The above research data was presented at the annual meeting of American Society of Clinical Oncology (ASCO) 2017.
However, Celsion’s shares have significantly underperformed the Zacks classified Medical-Biomed/Genetics industry so far this year. The stock has plunged 43.1% compared with the broader industry’s increase of 8.1%.
With enrolment completion, the company remains on track for an investigational new drug (IND) submission for phase I/II clinical study, combining GEN-1 with Roche Holding AG’s (RHHBY - Free Report) Avastin and Doxil in the recurrent population of ovarian cancer patients.
Apart from GEN-1 immunotherapy, another cancer program in Celsion’s portfolio is ThermoDox. It is currently under scrutiny in a phase III study for primary liver cancer and a phase II study for recurrent chest wall breast cancer.
Celsion Corporation Price
Celsion Corporation Price | Celsion Corporation Quote
Zacks Rank & Key Picks
Celsion currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in healthcare space are Bayer AG (BAYRY - Free Report) and Aduro BioTech, Inc. . While Bayer sports a Zacks Rank #1 (Strong Buy), Aduro carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Bayer’s earnings per share estimates have inched up from $8.85 to $8.93 for 2017 and from $9.53 to $9.61 for 2018, over the last 30 days. The company has delivered positive earnings surprises in three of the four trailing quarters with an average beat of 10.25%. Shares of Bayer have soared 22.6% so far this year.
Aduro’s loss per share estimates has shrunk from $1.60 to $1.46 for 2017 in the last 60 days. The company has delivered positive earnings surprises in two of the four trailing quarters with an average beat of 36.28%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>